BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22011217)

  • 1. Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: clinical and instrumental evaluation.
    Colonna L; Pacifico V; Lello S; Sorge R; Raskovic D; Primavera G
    J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1364-71. PubMed ID: 22011217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations.
    Lello S; Primavera G; Colonna L; Vittori G; Guardianelli F; Sorge R; Raskovic D
    Gynecol Endocrinol; 2008 Dec; 24(12):718-23. PubMed ID: 19172543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ethinyl estradiol and desogestrel on clinical and metabolic parameters in Indian patients with polycystic ovary syndrome.
    Bhattacharya SM; Ghosh M; Basu R
    J Obstet Gynaecol Res; 2012 Jan; 38(1):285-90. PubMed ID: 22070369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
    Uras R; Orrù M; Pani F; Marotto MF; Pilloni M; Guerriero S; Etzi R; Zedda P; Sorge R; Lello S; Melis GB; Paoletti AM
    Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
    van Vloten WA; van Haselen CW; van Zuuren EJ; Gerlinger C; Heithecker R
    Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of chlormadinone acetate versus drospirenone-containing oral contraceptives on the endocrinal features of women with polycystic ovary syndrome: Systematic review and meta-analysis of randomized clinical trials.
    Menshawy A; Ismail A; Abdel-Maboud M; El-Din AA; Elgebaly A; Gadelkarim M; Bahbah EI; Abdelghany MF; Samy A; Abbas AM
    J Gynecol Obstet Hum Reprod; 2019 Nov; 48(9):763-770. PubMed ID: 30940512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone).
    Podfigurna A; Meczekalski B; Petraglia F; Luisi S
    J Endocrinol Invest; 2020 Apr; 43(4):483-492. PubMed ID: 31654312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.
    Plewig G; Cunliffe WJ; Binder N; Höschen K
    Contraception; 2009 Jul; 80(1):25-33. PubMed ID: 19501212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
    Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
    Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome.
    Cinar N; Harmanci A; Bayraktar M; Yildiz BO
    Clin Endocrinol (Oxf); 2013 Mar; 78(3):379-84. PubMed ID: 22509734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
    Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
    Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
    Thorneycroft lH; Gollnick H; Schellschmidt I
    Cutis; 2004 Aug; 74(2):123-30. PubMed ID: 15379365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome.
    De Leo V; Di Sabatino A; Musacchio MC; Morgante G; Scolaro V; Cianci A; Petraglia F
    Contraception; 2010 Sep; 82(3):276-80. PubMed ID: 20705157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up.
    Yildizhan R; Gokce AI; Yildizhan B; Cim N
    Gynecol Endocrinol; 2015 May; 31(5):396-400. PubMed ID: 25739031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ethinylestradiol/cyproterone acetate on endothelial function in young non-obese women with polycystic ovary syndrome: a pilot study.
    Naka KK; Kalantaridou SN; Bechlioulis A; Kravariti M; Kazakos N; Katsouras CS; Tsatsoulis A; Michalis LK
    Gynecol Endocrinol; 2011 Sep; 27(9):615-21. PubMed ID: 21329419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the use of combined oral contraceptives amongst women with and without acne.
    Seaman HE; de Vries CS; Farmer RD
    Hum Reprod; 2003 Mar; 18(3):515-21. PubMed ID: 12615817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris.
    Palli MB; Reyes-Habito CM; Lima XT; Kimball AB
    J Drugs Dermatol; 2013 Jun; 12(6):633-7. PubMed ID: 23839178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperandrogenemia association with acne and hirsutism severity in Croatian women with polycystic ovary syndrome.
    Pavičić Baldani D; Škrgatić L; Bukvić Mokos Z; Trgovčić I
    Acta Dermatovenerol Croat; 2013; 21(2):105-12. PubMed ID: 24001418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome.
    Morgante G; Cappelli V; Troìa L; De Leo V
    Eur J Contracept Reprod Health Care; 2020 Jun; 25(3):176-181. PubMed ID: 32191532
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.